Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
03:20pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
09:11am, Friday, 29'th Apr 2022
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
09:50pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed at $210.41 in the latest trading session, marking a +1.68% move from the prior day.
Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?
02:24pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
10:00pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $206.94, marking a -0.02% move from the previous day.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
04:44pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
04:17pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
Biogen: Medicare Setback May Trigger Innovation And Partnerships
01:32pm, Wednesday, 27'th Apr 2022
On April 7, 2022, Medicare declined coverage of amyloid-based therapies without proven clinical benefit. This exceptional decision is a setback for Biogen, but investors were expecting it.
These 21 large-cap stocks have now crashed at least 50%
01:20pm, Wednesday, 27'th Apr 2022 MarketWatch
Pummeled stocks include Netflix, PayPal and Facebook parent Meta Platforms.
Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?
12:35pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
07:01pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
04:33pm, Tuesday, 26'th Apr 2022
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Things Just Got Worse for Biogen
12:03pm, Tuesday, 26'th Apr 2022 The Motley Fool
The company just withdrew its Aduhelm regulatory submission in the EU.
Things Just Got Worse for Biogen
08:03am, Tuesday, 26'th Apr 2022
The company just withdrew its Aduhelm regulatory submission in the EU.
Sarepta: The DMD Leader
05:05am, Tuesday, 26'th Apr 2022 Seeking Alpha
Sarepta is the unrivalled leader in the DMD or Duchenne Muscular Dystrophy space. Its revenue stream is growing tremendously over the years.
